Steady-State Pharmacokinetics of Nitrendipine in Hepatic Insufficiency

Kc, Lasseter; Ec, Shamblen; Aa, Murdoch; De, Burkholder; Gj, Krol; Rj, Taylor; Sk, Vanov

doi:10.1097/00005344-198400067-00010

Cited by 33 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition when the AUC values found in this study are compared to published data (Lasseter et al, 1984;Kann et al, 1984) in young volunteers, it would appear that elderly patients do have on average higher AUC values.…”

Section: Discussionsupporting

confidence: 61%

Plasma nitrendipine concentrations in elderly hypertensive patients after single and multiple dosing.

Crome

Baksi

MacMahon

et al. 1988

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 61%

Plasma nitrendipine concentrations in elderly hypertensive patients after single and multiple dosing.

Crome

Baksi

MacMahon

et al. 1988

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…The median peak plasma concentration of nitrendipine was somewhat lower than that reported in two studies of normal non-pregnant adults (Aronoff, 1984;Kann et al, 1984) but within a similar range for a third study (Lasseter et al, 1984). The subjects in the non-pregnant studies were all male, and the dose per kilogram bodyweight will have been some 20% higher in the patients of this paper.…”

Section: Plasma Nitrendipine Concentrationssupporting

confidence: 50%

Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy.

Lawrence

Pipkin

1987

Brit J Clinical Pharma

View full text Add to dashboard Cite

The effects of a dihydropyridine calcium channel antagonist, nitrendipine 20 mg orally, have been investigated in 24 women in the first trimester human pregnancy in a double‐blind, placebo controlled study. The effects on systemic arterial pressure, pulse rate (PR), blood loss at termination of pregnancy (TOP), plasma renin, renin substrate and aldosterone concentrations and platelet aggregation to adenosine diphosphate 0.5 microM, adrenaline bitartrate 0.1‐1.0 microM, thrombin 0.05 u ml‐1 and sodium arachidonate 0.1‐0.2 mM were studied. Administration of nitrendipine was associated with a statistically‐ significant fall in diastolic pressure (BPD) the magnitude of which was directly related to the individual peak concentrations of the drug (P less than 0.02). No significant effects were observed on systolic pressure (BPS);PR rose slightly. Baseline variability of all three parameters fell in the nitrendipine‐treated group over the first 2 h but then increased significantly (BPS, P less than 0.05; BPD, P less than 0.025; PR, P less than 0.005). There was a positive association in both placebo and treated groups between the rates of change of BPD and PR (P less than 0.005 for both); nitrendipine exerted a highly significant (P less than 0.001) effect on this association compatible with its effect as a vasodilator. Blood loss consequent on TOP did not differ in the two groups (nitrendipine 104 +/‐ 16 ml; placebo 114 +/‐ 20 ml). There were no significant differences in basal or stimulated hormone concentrations in the two groups. The ex vivo platelet aggregatory response in whole blood to 0.1 mM sodium arachidonate was inhibited by nitrendipine (P less than 0.05); responsiveness to the other aggregatory agents studied was not changed. There was a wide individual variation in both time to peak concentration of nitrendipine and the size of the peak, making classical pharmacokinetic analysis impossible. The median time after ingestion to peak concentration was 105 min; the median concentration was 7.8 ng ml‐1. These data suggest that, in the context of the severe vasoconstriction and platelet aggregability of pregnancy‐induced hypertension, further studies of this drug in pregnancy are warranted.

show abstract

“…From this, the nitrendipine concentration necessary to produce a certain effect was determined. Other investigators have reported a significant relationship between reduction of blood pressure and plasma nitrendipine concentrations in patients with renal failure (Lasseter et al, 1984;Lettieri etal., 1987), but no regression analysis was performed to assess the plasma nitrendipine concentration required to achieve a defined blood pressure lowering effect.…”

Section: Discussionmentioning

confidence: 95%

Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension.

Mikus

Mast

Fischer

et al. 1991

Brit J Clinical Pharma

View full text Add to dashboard Cite

Steady-State Pharmacokinetics of Nitrendipine in Hepatic Insufficiency

Cited by 33 publications

References 0 publications

Plasma nitrendipine concentrations in elderly hypertensive patients after single and multiple dosing.

Plasma nitrendipine concentrations in elderly hypertensive patients after single and multiple dosing.

Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy.

Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension.

Contact Info

Product

Resources

About